APA (7th ed.) Citation

Hovinga, K. E., McCrea, H. J., Brennan, C., Huse, J. T., Zheng, J., Esquenazi, Y., . . . Tabar, V. (2019). EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.

Chicago Style (17th ed.) Citation

Hovinga, Koos E., Heather J. McCrea, Cameron Brennan, Jason T. Huse, Junting Zheng, Yoshua Esquenazi, Katherine S. Panageas, and Viviane Tabar. EGFR Amplification and Classical Subtype Are Associated with a Poor Response to Bevacizumab in Recurrent Glioblastoma. 2019.

MLA (9th ed.) Citation

Hovinga, Koos E., et al. EGFR Amplification and Classical Subtype Are Associated with a Poor Response to Bevacizumab in Recurrent Glioblastoma. 2019.